Person: Peter Frawley

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

business

Elan starts to produce MS drug

ELAN has started production of Antegren, its multiple sclerosis (MS) drug, in advance of a possible launch in 2005.

business

Galen unveil chewable ‘Pill’

business

Elan sales stronger than expected

world

Two former Elan chiefs on full pay

business

Losses mount at beleaguered Elan

world

Elan, Biogen shares rise on drug trials

Elan on track for €844m loss this year, according to analysts

ELAN is on course to make losses of €844.8 million this year, according to Davy Stockbrokers who do not expect the company to return to profitability in 2003.

Thu, 24 Oct, 2002

Debtors threaten to seize control of Elan

BONDHOLDERS in Elan owed in excess of €1 billion may take control of the company if Elan's share price does not rise significantly when the debts mature in December 2003.

Thu, 11 Jul, 2002

Elan shares blackballed by brokers

ELAN shares have been given an "avoid" rating by Merrion Stockbrokers in the wake of the company's global conference call to investors yesterday when plans to raise €1 billion in an asset sell-off were unveiled.

Wed, 10 Jul, 2002